Chronic and opportunistic infections in patients with immuno-inflammatory rheumatic diseases: screening and prevention issues (based on the materials of the EULAR recommendations)
暂无分享,去创建一个
G. Gridneva | E. Nasonov | E. Aronova | B. Belov | B. S. Belov | G. I. Gridneva | E. S. Aronova | E. L. Nasonov
[1] J. Bijlsma,et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases , 2022, Annals of the Rheumatic Diseases.
[2] J. Schoones,et al. Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases , 2022, RMD Open.
[3] G. Gridneva,et al. Current issues in the management of patients with HIV infection and rheumatic diseases , 2021, Modern Rheumatology Journal.
[4] Yoshiya Tanaka,et al. Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry , 2021, Rheumatology.
[5] J. Saegusa,et al. Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids , 2021, Rheumatology International.
[6] E. Lee,et al. Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. , 2021, Clinical and experimental rheumatology.
[7] Y. Tagashira,et al. Reduction of Pneumocystis jirovecii pneumonia and bloodstream infections by trimethoprim–sulfamethoxazole prophylaxis in patients with rheumatic diseases , 2021, Scandinavian journal of rheumatology.
[8] Chi-Ching Chang,et al. Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study , 2021, Clinical Rheumatology.
[9] Pengchong Li,et al. Tuberculosis in patients with systemic lupus erythematosus–a 37‐year longitudinal survey‐based study , 2020, Journal of internal medicine.
[10] A. Yamasaki,et al. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with rheumatic diseases , 2020, Modern rheumatology.
[11] P. V. Casasempere,et al. Pneumocystis jirovecii in immunocompromised patients with rheumatic diseases , 2020 .
[12] T. Shim,et al. Early discontinuation of tofacitinib in patients with rheumatoid arthritis co-treated with rifampin for latent tuberculosis. , 2020, Joint bone spine.
[13] M. Tong,et al. Reactivation of Hepatitis B Virus: A Review of Clinical Guidelines , 2020, Clinical liver disease.
[14] Yi‐Hsiang Huang,et al. Low but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] Karina D. Torralba,et al. Screening for acquired latent tuberculosis in rheumatoid arthritis patients on tumor necrosis factor inhibition therapy in Southern California , 2020, Clinical Rheumatology.
[16] Xinyi Wang,et al. High risk of activation of latent tuberculosis infection in rheumatic disease patients , 2020, Infectious diseases.
[17] T. Hanyu,et al. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital , 2019, Arthritis Research & Therapy.
[18] E. Lee,et al. Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole , 2019, Arthritis Research & Therapy.
[19] V. Sundararajan,et al. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents. , 2019, Clinics in liver disease.
[20] H. Kikuchi,et al. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[21] W. Grassi,et al. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis , 2019, Modern rheumatology.
[22] A. Granel,et al. Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy , 2018, European journal of rheumatology.
[23] M. Okada,et al. Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease? , 2018, Annals of the rheumatic diseases.
[24] C. Mok. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. , 2018, Best practice & research. Clinical rheumatology.
[25] T. Shim,et al. The usefulness of routine chest radiograph examinations in patients treated with TNF inhibitors for inflammatory arthritis in South Korea. , 2018, Respiratory medicine.
[26] A. Geier,et al. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs—a single-center analysis of 2054 patients , 2018, Clinical Rheumatology.
[27] N. Baykam,et al. Clinical, radiological and prognostic features of influenza cases in the influenza epidemic during years 2016-2017. , 2018, Tuberkuloz ve toraks.
[28] B. McMahon,et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.
[29] A. Ustianowski,et al. Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy , 2018, Rheumatology.
[30] M. Little,et al. The complications of vasculitis and its treatment. , 2018, Best practice & research. Clinical rheumatology.
[31] E. Lee,et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids , 2017, Annals of the rheumatic diseases.
[32] J. Peacock,et al. Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented? , 2017, Current Rheumatology Reports.
[33] M. Tomita,et al. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial , 2017, Arthritis Research & Therapy.
[34] J. Gómez-Reino,et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis , 2015, Annals of the rheumatic diseases.
[35] C. Bombardier,et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications , 2015, Thorax.
[36] K. Reddy,et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. , 2015, Gastroenterology.
[37] Jing-wen Ai,et al. Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis , 2016, Clinical Rheumatology.
[38] A. Lok,et al. Management of patients with hepatitis B who require immunosuppressive therapy , 2014, Nature Reviews Gastroenterology &Hepatology.
[39] D. Choquette,et al. Increased incidence of liver enzymes abnormalities in patients treated with isoniazid in combination with disease modifying and/or biologic agents , 2014, Clinical Rheumatology.
[40] L. Punzi,et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients , 2014, Clinical Rheumatology.
[41] C. Massone,et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. , 2011, Rheumatology.
[42] L. Stamp,et al. Is There a Role for Consensus Guidelines for P. jiroveci Pneumonia Prophylaxis in Immunosuppressed Patients with Rheumatic Diseases? , 2010, The Journal of Rheumatology.
[43] C. Vogel,et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. , 2008, Rheumatology.
[44] Mahboob Rahman,et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. , 2006, Arthritis and rheumatism.
[45] P. Geusens,et al. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors , 2003, Annals of the rheumatic diseases.
[46] P. Thompson,et al. Rifampicin reduces effectiveness and bioavailability of prednisolone. , 1983, British medical journal.